Press "Enter" to skip to content

Heart Transplant ‘Liquid Biopsy’; PCSK9 CRISPR; More SGLT2 Drugs Try FDA in HF

A blood test showed promise as a “liquid biopsy” for detection of acute heart transplant rejection. (Circulation)

Early efforts to use CRISPR to edit PCSK9 genes in severe heterozygous familial hypercholesterolemia are moving forward. (Endpoints News)

In a study of 145 student athletes with no more than moderate COVID-19 symptoms, cardiac MRI a median 15 days after the positive test was consistent with myocarditis in two (1.4%). (JAMA Cardiology)

Each extra serving of fried foods per week was linked to 3% more major cardiovascular events, 2% more coronary heart disease, and 12% more heart failure risk. (Heart)

Empagliflozin (Jardiance) is getting FDA review to reduce risk of cardiovascular death and hospitalization for heart failure and to slow kidney function decline in adults with chronic heart failure with reduced ejection fraction, irrespective of type 2 diabetes, based on the phase III EMPEROR-Reduced trial, Boehringer Ingelheim and Eli Lilly announced.

Sotagliflozin may have another shot with the FDA, after the agency gave the green light to use of the SOLOIST and SCORED trials to support a new drug application in reducing risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adults with type 2 diabetes and either worsening heart failure or additional risk factors for heart failure. (Yahoo! Finance)

Even short-term exposure to air pollution is linked to heart attack deaths, Chinese data showed in the Journal of the American College of Cardiology.

Recent findings on risks from paclitaxel-based devices for peripheral arterial disease have been “comforting” but not enough to support new guidance, FDA leaders wrote in the New England Journal of Medicine.

Women were more likely than men to be readmitted for heart failure after a heart attack, according to a study in Heart.

Penumbra’s Indigo Aspiration System’s safety and efficacy in pulmonary embolism treatment that led to recent FDA clearance are published in JACC: Cardiovascular Interventions.

Two interventional cardiologists won an arbitration decision over losing leadership positions at Detroit Medical Center after coming forward with concerns about dirty instruments, unnecessary medical procedures, and inappropriate billing practices. (Cardiovascular Business)

Heart Failure Association of America past president Barry Massie, MD, died. (St. Louis Post-Dispatch)

Source: MedicalNewsToday.com